Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.11 +0.01 (+8.00%)
As of 11:42 AM Eastern
Compare

OBD vs. APTA, FAB, RLM, NSCI, and GENF

Should you buy Oxford BioDynamics stock or one of its competitors? MarketBeat compares Oxford BioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford BioDynamics include Aptamer Group (APTA), Fusion Antibodies (FAB), Realm Therapeutics (RLM), NetScientific (NSCI), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to Aptamer Group?

Oxford BioDynamics (LON:OBD) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Aptamer Group Neutral

Aptamer Group has higher revenue and earnings than Oxford BioDynamics. Aptamer Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M3.88-£103.52M-£0.20N/A
Aptamer Group£1.38M11.28-£14.17M-£0.11N/A

Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, indicating that its stock price is 10% less volatile than the broader market.

Aptamer Group has a net margin of -178.52% compared to Oxford BioDynamics' net margin of -825.61%. Aptamer Group's return on equity of -135.35% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Aptamer Group -178.52%-135.35%-44.96%

25.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 7.3% of Aptamer Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aptamer Group beats Oxford BioDynamics on 8 of the 11 factors compared between the two stocks.

How does Oxford BioDynamics compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Fusion Antibodies has a net margin of -91.92% compared to Oxford BioDynamics' net margin of -825.61%. Fusion Antibodies' return on equity of -210.32% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Oxford BioDynamics -825.61%-451.74%-56.23%

Fusion Antibodies has a beta of 1.224, indicating that its share price is 22% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 25.3% of Oxford BioDynamics shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Fusion Antibodies has higher revenue and earnings than Oxford BioDynamics. Fusion Antibodies is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A
Oxford BioDynamics£1.20M3.88-£103.52M-£0.20N/A

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Oxford BioDynamics Neutral

Summary

Fusion Antibodies beats Oxford BioDynamics on 6 of the 11 factors compared between the two stocks.

How does Oxford BioDynamics compare to Realm Therapeutics?

Realm Therapeutics (LON:RLM) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Realm Therapeutics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Realm Therapeutics Neutral
Oxford BioDynamics Neutral

Realm Therapeutics has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Realm Therapeutics£501.92K0.00N/A-£17.50N/A
Oxford BioDynamics£1.20M3.88-£103.52M-£0.20N/A

Realm Therapeutics has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Realm Therapeutics' return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Realm TherapeuticsN/A N/A N/A
Oxford BioDynamics -825.61%-451.74%-56.23%

25.3% of Oxford BioDynamics shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Oxford BioDynamics beats Realm Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Oxford BioDynamics compare to NetScientific?

Oxford BioDynamics (LON:OBD) and NetScientific (LON:NSCI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

NetScientific has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M3.88-£103.52M-£0.20N/A
NetScientific£1.45M0.00-£2.64M-£0.11N/A

NetScientific has a net margin of -182.91% compared to Oxford BioDynamics' net margin of -825.61%. NetScientific's return on equity of -13.70% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
NetScientific -182.91%-13.70%-9.42%

25.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 42.4% of NetScientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled NetScientific'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
NetScientific Neutral

Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, NetScientific has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Summary

NetScientific beats Oxford BioDynamics on 8 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to Genflow Biosciences?

Oxford BioDynamics (LON:OBD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Genflow Biosciences has lower revenue, but higher earnings than Oxford BioDynamics. Genflow Biosciences is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M3.88-£103.52M-£0.20N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Genflow Biosciences Neutral

Oxford BioDynamics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, suggesting that its stock price is 130% more volatile than the broader market.

25.3% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genflow Biosciences has a net margin of -170.64% compared to Oxford BioDynamics' net margin of -825.61%. Genflow Biosciences' return on equity of 332.06% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Genflow Biosciences -170.64%332.06%-58.66%

Summary

Oxford BioDynamics and Genflow Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.63M£517.61M£7.06B£2.84B
Dividend YieldN/A3.90%2.68%6.17%
P/E Ratio-0.543.4727.15368.18
Price / Sales3.886,436.17526.8984,612.72
Price / Cash3.9813.1329.2227.87
Price / Book0.1385.9310.757.49
Net Income-£103.52M-£96.07M£3.58B£5.89B
7 Day Performance-1.82%-1.18%-2.10%-0.48%
1 Month Performance-40.33%2.45%3.32%-1.00%
1 Year Performance-58.30%60.93%28.17%61.74%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.11
+8.0%		N/A-61.4%£4.63M£1.20MN/A45
APTA
Aptamer Group
N/AGBX 0.47
-1.1%		N/A+20.8%£16.24M£1.38MN/A37
FAB
Fusion Antibodies
N/AGBX 11.50
-4.2%		N/A+69.3%£14.38M£1.60MN/A48
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 7/13/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel